Sepranolone

DB12972InvestigationalSmall molecule

Sepranolone has been investigated for the treatment of Premenstrual Dysphoric Disorder.

Chemical structure of Sepranolone
Mechanism
Curator reviewed
Formula / weight
C21H34O2 · 318.4935 g/mol (avg)
Code names
NSC-97078 · U-0949 · UC-1010

Resolves to

Compound
UNII3P8Z6V53MUCAS516-55-2ChEMBLCHEMBL2057301ChEBI11909PubChem92787KEGGC15484
Structure
InChIKeyAURFZBICLPNKBZ-FZCSVUEKSA-NSMILES[H][C@@]12CC[C@H](C(C)=O)[C@@]1(C)CC[C@@]1([H])[C@@]2([H])CC[C@@]2([H])C[C@@H](O)CC[C@]12C

What you can answer from here — as of July 07, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action
Listed above
4Clinical trialsPhase, status and sponsor resolved per trial
Sign in
1+ReferenceStructured and connected to the statements they support
Sign in

Which companies are running trials of Sepranolone, in which indications and phases, and which of those programs are still active?

Answer this in Biopharma OSSign in to your account

Create a free account or log in to explore the full data card.

Create Account
Log InPaid Account Log In